# overweight or obesity FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/overweight-or-obesity

> 2 upcoming FDA catalysts in overweight or obesity: olatorepatide (REGN) on Jan to Apr 2028 (topline data readout); olatorepatide (REGN) on January 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Q1 2025 | [WVE-007 trial start](https://sec-api.dev/pdufa/wve-007) | WVE | overweight or obesity | scheduled | "We are on track to initiate a Phase 1 clinical trial for WVE-007 in adults living with overweight or obesity in the first quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1631574/000095017024124595/wve-20240930.htm)) |
| Nov 2026 to Feb 2027 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431086)) |
| November 2026 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07431086 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-13 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431086)) |
| Jan to Apr 2028 | [Olatorepatide topline data readout](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07685808)) |
| January 2028 | [Olatorepatide primary completion](https://sec-api.dev/pdufa/olatorepatide) | REGN | Overweight or Obesity | scheduled | "NCT07685808 (Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-21 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07685808)) |

## Drugs

- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)
- [Olatorepatide](https://sec-api.dev/pdufa/olatorepatide) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/overweight-or-obesity.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "overweight or obesity FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/overweight-or-obesity

```bibtex
@misc{secapidev_indications_overweight_or_obesity_20261116,
  title        = {overweight or obesity FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/overweight-or-obesity}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_overweight_or_obesity_20261116","title":"overweight or obesity FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/overweight-or-obesity","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
